// App-Quantinova.ai

474 : Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma

Researchers

Presenter

  • Alex F. Herrera

Principal Investigators

  • Carmelo Carlo-Stella

  • Graham P. Collins

  • Kami J. Maddocks

  • Nancy L. Bartlett

  • Kerry J. Savage

  • Paolo F Caimi

  • Brian T. Hess

  • Pier Luigi Zinzani

  • Hans G Cruz

  • Luqiang Wang

  • Jay Feingold

  • Jens Wuerthner

  • Stephen M. Ansell

Medical Centers

  • Department of Hematology and Hematopietic Cell Transplantation, City of Hope, Duarte, CA

  • Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Milano, Italy

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH

  • Division of Oncology, Washington University in St. Louis, St. Louis, MO

  • Department of Pathology, BC Cancer Agency and University of British Columbia, Vancouver, BC, Canada

  • University Hospitals Cleveland Medical Center / Case Western Reserve University School of Medicine, Cleveland, OH

  • Division of Hematology and Medical Oncology, Department of Medicine,Medical University of South Carolina,Charleston,États-unis

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • Clinical Development, ADC Therapeutics, Epalinges, Switzerland

  • ADC Therapeutics America, Inc, Murray Hill

  • ADC Therapeutics America, Inc, Murray Hill

  • Mayo Clinic, Rochester, MN

Locations

  • United States

  • Italy

  • United Kingdom

  • Canada

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

Biomarkers

  • Programmed cell death protein 1

Drug/Treatment

  • ADCT301

  • Adcetris

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • NCT04052997

Sponsors

  • ADC Therapeutics

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved